TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Cambridge, Massachusetts, UNITED STATES

- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial
- IND Clearance for Phase 1/2 clinical trial of TC-510
- 30 patients treated with gavo-cel in the expanded Phase 1 trial; dataset review in July 2022
- Updates anticipated in the second half of 2022